Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha

British Journal of Haematology

Volumn 121, Issue 1, 2003, Pages 101-103

  Steurer, Michael ^a   Sudmeier, Irene ^a   Stauder, Reinhard ^a   Gastl, Günther ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Darbepoietin; Myelodysplastic syndrome; Thalidomide; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; MYRIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; THALIDOMIDE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LUNG EMBOLISM; MORBIDITY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; THROMBOEMBOLISM; THROMBOGENICITY;

AGED; ANTICOAGULANTS; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PULMONARY EMBOLISM; THALIDOMIDE; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0037393945     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04252.x     Document Type: Article

References (12)

1. Cavo, M., Zamagni, E., Cellini, C., Tosi, P., Cangini, D., Cini, M., Valdré, L., Palareti, G., Masini, L., Tura, S. & Baccarani, M. (2002) Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone treatment. Blood, 100, 2271-2272.
2. Escudier, B., Lassau, N., Couanet, D., Angevin, E., Mesrati, F., Leborgne, S., Garofano, A., Leboulaire, C., Dupouy, N. & Laplanche, A. (2002) Phase II trial of thalidomide in renal-cell carcinoma. Annals of Oncology, 13, 1029-1035.
3. Musto, P., Falcone, A., Bodenizza, C., Sanpaolo, G., Cascavilla, N., Malillo, L., Nobile, M., Dell'Olio, M. & Carella, A.M. (2002) High efficacy of thalidomide in selected patients with transfusion-dependent myelodysplastic syndromes. Hematology Journal, 3, 1061a.
4. Raza, A., Meyer, P., Dutt, D., Zorat, F., Lisak, L., Nascimben, F., du Randt, M., Kaspar, C., Goldberg, C., Loew, J., Dar, S., Gezer, S., Venugopal, P. & Zeldis, J. (2001) Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood, 98, 958-965.
5. Rose. E.H., Abels, R.I., Nelson, R.A., McCullough, D.M. & Lessin, L. (1995) The use of r-HuEpo in the treatment of anaemia related to myelodysplasia. British Journal of Haematology, 89, 831-837.
6. Smith, R. (2002) Applications of darbepoietin-alfa, a novel erythropoiesis-stimulating protein, in oncology. Current Opinions in Hematology, 9, 228-233.
7. Stohlawetz, P.J., Dzirlo, L., Hergovich, N., Lackner, E., Mensik, C., Eichler, H.G., Kabrna, E., Geissler, K. & Jilma, B. (2000) Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood, 95, 2983-2989.
8. Strupp, C., Germing, U., Aivado, M., Misgeld, E., Haas, R. & Gattermann, N. (2002) Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia, 16, 1-6.
9. Terpos, E., Mougiou, A., Kouraklis, A., Chatzivassili, A., Michaeli, E., Giannakoulas, N., Manioudaki, E., Lazaridou, A., Bakaloudi, V., Protopappa, M., Liapi, D., Grouzi, E., Parharidou, A., Symeonidis, A., Kokkini, G., Laoutaris, N.P., Vaipoulos, G., Anagnostopoulos, N.I., Christakis, J.I., Meletis, J., Bourantas, K.L., Zoumbos, N.C., Yataganas, X. & Viniou, N.A. for the Greek MDS Study Group (2002) Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. British Journal of Haematology, 118, 174-180.
10. Urbauer, E., Kaufmann, H., Nösslinger, T., Raderer, M. & Drach, J. (2002) Thromboembolic events during treatment with thalidomide. Blood, 99, 4247-4248.
11. Vansteenkiste, J., Pirker, R., Massuti, B., Barata, F., Font, A., Fiegl, M., Siena, S., Gateley, J., Tomita, D., Colowick, A.B. & Musil, J. (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoietin alfa in lung cancer patients receiving chemotherapy. Journal of the National Cancer Institute, 94, 1211-1220.
12. Zangari, M., Siegel, E., Barlogie, B., Anaissie, E., Saghafifar, F., Fassas, A., Morris, C., Fink, L. & Tricot, G. (2002) Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood, 100, 1168-1171.